Search clinical trials for: factor VIII prophylaxis

Total 38617 results

Baxalta now part of Shire
Baxter Innovations GmbH

Completed

Phase 1/2 Lyme Vaccine Study

Prophylaxis of Lyme Borreliosis

Germany, Austria
Baxalta now part of Shire

Completed

China ADVATE PTP Study

Hemophilia A

China
Baxalta now part of Shire

Completed

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

Von Willebrand Disease

United States, Germany, United Kingdom, Italy, Austria, Canada
Baxalta now part of Shire

Completed

Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients

Hemophilia A

Czechia, Bulgaria, Hungary, Poland
University of British Columbia
Biogen

Completed

Factor Product Utilization and Health Outcomes in Patients With Hemophilia

Hemophilia A, Congenital | Hemophilia B, Congenital

Canada
Baxalta now part of Shire

Completed

Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

Hemophilia A

United States, Canada, Puerto Rico
University of Cologne

Completed

Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT (OCTET-Ever)

Graft-versus-Host Disease

Germany
Baxalta now part of Shire

Completed

Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A

Hemophilia A

China
Baxalta now part of Shire

Completed

ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)

Hemophilia A | Congenital Factor VIII (FVIII) Deficiency

United Kingdom, France, Germany, Hungary
Baxalta now part of Shire

Completed

GAS-Hem Feasibility Study

Hemophilia A

Canada, United States
McMaster University
Canadian Hemophilia Society

Completed

Web-based Application for the Population Pharmacokinetic Service - Phase 1 (WAPPS)

Hemophilia A | Hemophilia B

Canada
Boston VA Research Institute, Inc.
University of Michigan; Emory University; Shire

Withdrawn

Improved Factor VIII Inhibitor Evaluation (IFIE)

Hemophilia A | Hemophilia

United States
Octapharma

Terminated

Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq (PREVAIL)

Hemophilia A

Canada
Hasan Kalyoncu University

Unknown

Effect of Exercise in Pediatric Hemophilia

Hemophilia Arthropathy | Hemophilia A, Severe

Turkey
Instituto de Investigacion Sanitaria La Fe
Bristol-Myers Squibb

Terminated

Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs

Venous Thromboembolism

Spain
Octapharma

Completed

Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients

Severe Hemophilia A

Canada, United States, France, Spain, Ukraine, United Kingdom, Belarus, Georgia, Germany, India, Italy, Moldova, Republic of, Morocco, Poland, Portugal, Russian Federation, Slovenia
Octapharma

Completed

Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A

Severe Hemophilia A

Bulgaria, Poland, Hungary, Romania, Russian Federation
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

Severe Hemophilia A

United States, United Kingdom, Spain, Hong Kong, Israel, New Zealand, Sweden, Australia, Brazil, Japan, Austria, Belgium, Italy, India, Switzerland, Canada, France, Germany, South Africa
Children's Mercy Hospital Kansas City

Terminated

A Study Comparing Factor Level and Inhibitor Titer Testing Results Drawn From Central Venous Lines and Venipuncture (CVL#2)

Hemophilia A | Hemophilia B | Hemophilia | Factor IX Deficiency | Factor VIII Deficiency

United States
Bayer

Completed

Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII)

Hemophilia A

Bulgaria
Bioverativ Therapeutics Inc.

Completed

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A (ASPIRE)

Hemophilia A

United States, Canada, Italy, Australia, Austria, Belgium, Brazil, France, Germany, Hong Kong, India, Ireland, Israel, Japan, Netherlands, New Zealand, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom
Bioverativ Therapeutics Inc.

Completed

Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

Severe Hemophilia A

United States, Hong Kong, Israel
Bioverativ Therapeutics Inc.

Completed

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

Severe Hemophilia A

United States, United Kingdom, Australia
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale (Elevate)

Severe Hemophilia A

United States, Australia, New Zealand
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A (Kids ALONG)

Hemophilia A

United States, Poland, United Kingdom, Netherlands, South Africa, Hong Kong, Australia, Ireland
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Terminated

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes (FORWARD)

Hemophilia A | Hemophilia B

United States
Takeda

Withdrawn

A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

Non-Small Cell Lung Cancer (NSCLC)
City of Hope Medical Center
CSL Behring; Grifols Therapeutics LLC; Grifols Biologicals, LLC; Charta Foundation and other collaborators

Withdrawn

Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive (RESIST NAIVE)

Severe Hemophilia A
Medical University of Gdansk
Baxter Healthcare Corporation

Unknown

Impact of Continuous Veno-venous Hemodiafiltration on Efficacy of Administration of Prophylactic Doses of Enoxaparin or Fondaparinux in Critically Ill Patients.

Assessment of Activity of Anti-Xa Factor in Patients Treated With Continuous Veno-venous Hemodiafiltration Receiving Anticoagulant Prophylaxis

Poland
Bayer

Terminated

Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors

Hemophilia A and B

Australia, United Kingdom, Taiwan, Japan, Korea, Republic of, Austria, Bulgaria, Hungary, Italy, France, New Zealand
St. Petersburg State Pavlov Medical University

Completed

GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

Acute Myeloid Leukemia | Leukemia, Acute Lymphoblastic | Mixed-Lineage Acute Leukemias

Russian Federation
Assistance Publique - Hôpitaux de Paris

Completed

Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT (ATG-CyGVHD)

Graft vs Host Disease

France
Peking University People's Hospital

Completed

Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis

Leukemia, GVHD, ATG, Transplantation

China
National Institute of Allergy and Infectious Diseases...
Rho Federal Systems Division, Inc.

Terminated

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation (deLTa)

Liver Transplantation

United States
Hospital Regional Tlalnepantla

Completed

Prophylaxis of Periprosthetic Joint Infections With Calcium Sulfate Beads in Patients With Non-modifiable Risk Factors. (Stimulan)

Infection

Mexico
Biomedical Advanced Research and Development Authority
Rho, Inc.

Completed

BARDA Securing Anthrax Immunity For the Elderly (B-SAFE)

Anthrax

United States
Oregon Health and Science University

Completed

FEIBA and Use of Blood Products in Cardiac Surgery (FEIBA)

Cardiovascular Disease

United States
National University of Malaysia

Completed

Safety of Fondaparinux as Post Partum Thromboprophylaxis

Thromboembolism in the Puerperium

Malaysia
PTC Therapeutics
Genzyme, a Sanofi Company

Terminated

Study of Ataluren (PTC124) in Hemophilia A and B

Hemophilia A | Hemophilia B

United States, Canada, France, Italy
University of California, Davis

Terminated

INdividualized ITI Based on Fviii(ATE) Protection by VWF (INITIATE)

Hemophilia A | Hemophilia A With Inhibitor

United States
Ottawa Hospital Research Institute

Completed

Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia (REaCT-TC2)

Early Stage Breast Cancer

Canada
AbbVie
European Organisation for Research and Treatment of Cancer - EORTC

Completed

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (INTELLANCE-2)

Glioblastoma

United States, Australia, Austria, Belgium, Canada, Czechia, Finland, France, Germany, Hungary, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Singapore, Spain, Switzerland, Taiwan, United Kingdom
Regina Elena Cancer Institute
Icahn School of Medicine at Mount Sinai; University of Roma La Sapienza

Unknown

Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis | Relapse

United States, Italy
Assiut University

Completed

Re-evaluation of Some Old Rheumatoid Arthritis Therapy: A Randomized Controlled Trial

Rheumatoid Arthritis

Egypt
Victor Blanchette
Queen's University; Sydney Children's Hospitals Network; Royal Children's Hospital and other collaborators

Unknown

Evaluation of a Simple Pharmacokinetic Tool (myPKFiT™) to Guide Personalized Factor VIII Dosing in Patients With Hemophilia

Hemophilia A
Kaifeng Pharmaceutical (Group) Co., Ltd.
Beijing Furen Biomedical Research Institute Co., Ltd.

Unknown

A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Hemophilia A

China
Ain Shams University

Unknown

Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19

Coronavirus Disease (COVID-19)

Egypt
Ain Shams University

Unknown

Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19

Coronavirus Disease (COVID-19)

Egypt
Novo Nordisk A/S

Completed

Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period (guardian 10)

Congenital Bleeding Disorder | Haemophilia A

India
Brown University

Withdrawn

Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma (BrUOG-377)

Diffuse Large B Cell Lymphoma

United States

Search clinical trials for: factor VIII prophylaxis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations